Jeffrey Chapman is currently an Associate Principal Scientist at Merck, where they have developed various assays to characterize monoclonal antibodies and actively manage affinity characterization projects. With extensive experience in research and development of small molecule therapeutics and biologics, Jeffrey previously served as a Senior Scientist at Schering-Plough Research Institute before it merged with Merck in 2010. They started their career as a Research Technician at New York University Medical Center after earning a B.A. in Molecular Biology from Colgate University and an M.S. in Medical Microbiology from Long Island University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices